Loading...

IL-2, the next best thing in chronic GVHD therapy?

In this issue of Blood, Koreth et al have reported that interleukin-2 (IL-2) is effective in chronic graft-versus-host disease (cGVHD) patients who had failed up to two prior lines of therapy.(1)

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Curtis, Lauren M., Pavletic, Steven Z.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2016
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4937357/
https://ncbi.nlm.nih.gov/pubmed/27389542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-711796
Tags: Add Tag
No Tags, Be the first to tag this record!